Search results for " type 2"

showing 10 items of 761 documents

1267 HSP70-2 polymorphism as a risk factor for carotid plaque rupture and cerebral ischaemia in old type 2 diabetes-atherosclerotic patients.

2005

Patients with type 2 diabetes mellitus (NIDDM) are at risk for macrovascular disease complications, such as myocardial infarction (MI) or stroke from plaque rupture. Cytokines play a key role in plaque vulnerability. IFN-gamma inhibits collagen synthesis thereby affecting plaque stability. High IL-6, TNF-alpha, and dyslipidemia are risk factors for thrombosis. Abnormal increments of HSP70 in atherosclerotic plaques might lead to plaque instability and rupture caused by chronic inflammation, which up-regulates the expression of pro-inflammatory cytokines (IL-6 and TNF-alpha) in human monocytes. Studies of a polymorphic PstI site lying in the coding region at position 1267 of the HSP70-2 gene…

Carotid Artery DiseasesMaleAgingmedicine.medical_specialtyGenotypeArteriosclerosisType 2 diabetesGastroenterologyBrain IschemiaInterferon-gammaGene FrequencyRisk FactorsInternal medicinemedicineHumansCarotid StenosisHSP70 Heat-Shock ProteinsMyocardial infarctionRNA MessengerAllelesTriglyceridesMacrovascular diseaseAgedGlycated HemoglobinRupturePolymorphism Geneticbusiness.industryInterleukin-6Tumor Necrosis Factor-alphaType 2 Diabetes MellitusOdds ratioCholesterol LDLMiddle Agedmedicine.diseaseThrombosisEndocrinologyCarotid ArteriesDiabetes Mellitus Type 2Relative riskFemalebusinessDyslipidemiaDevelopmental BiologyMechanisms of ageing and development
researchProduct

Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospectiv…

2016

Abstract Background Liraglutide, a GLP-1 analogue, exerts several beneficial non-glycemic effects in patients with type-2 diabetes (T2DM), such as those on body weight, blood pressure, plasma lipids and inflammation markers. However, the effects of liraglutide on cardiovascular (CV) risk markers in subjects with the metabolic syndrome (MetS) are still largely unknown. We herein explored its effects on various cardio-metabolic risk markers of the MetS in subjects with T2DM. Methods We performed an 18-month prospective, real-world study. All subjects had T2DM and the MetS based on the AHA/NHLBI criteria. Subjects with a history of a major CV event were excluded. One hundred-twenty-one subject…

Carotid Artery DiseasesMaleEndocrinology Diabetes and MetabolismPredictive Value of Test030204 cardiovascular system & hematologyCarotid intima-media thickne0302 clinical medicineRisk FactorsPrevalenceProspective StudiesCarotid intima-media thicknessProspective cohort studyOriginal Investigation2. Zero hungerIncretinMiddle AgedMetabolic syndromeMetformin3. Good healthMetforminTreatment OutcomeItalyCardiologyDrug Therapy CombinationFemaleCardiology and Cardiovascular MedicineHumanmedicine.drugmedicine.medical_specialtyIncretin030209 endocrinology & metabolismIncretins03 medical and health sciencesPredictive Value of TestsInternal medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsCardiovascular risk Carotid intima-media thickness Liraglutide Metabolic syndromeAgedCarotid Artery DiseaseHypoglycemic AgentLiraglutidebusiness.industryRisk FactorBiomarkerLiraglutideCardiovascular riskmedicine.diseaseEchocardiography Doppler ColorProspective StudieDiabetes Mellitus Type 2Intima-media thicknessMetabolic syndromebusinessBody mass indexBiomarkersCardiovascular Diabetology
researchProduct

Carotid atherosclerosis and chronic hepatitis C: A prospective study of risk associations

2011

BACKGROUND AND AIMS: There are contrasting results in studies of cardiovascular risk in patients with genotype 1 chronic hepatitis C (G1 CHC). We evaluated the prevalence of carotid atherosclerosis compared with a control population in order to assess the potential association between atherosclerosis, host and viral factors, and liver histological features. MATERIALS AND METHODS: One hundred seventy-four consecutive biopsy-proven G1 CHC patients were evaluated by anthropometric and metabolic measurements. One hundred seventy-four patients attending an outpatient cardiology unit were used as controls. Intima-media thickness (IMT) and carotid plaques, defined as focal thickening of > 1.3 mm a…

Carotid Artery DiseasesMaleLIVER BIOPSYComorbiditySeverity of Illness IndexGastroenterologyBody Mass IndexReference ValuesOdds RatioPrevalenceProspective StudiesProspective cohort studySettore MED/12 - Gastroenterologiamedicine.diagnostic_testBiopsy NeedleSmokingHepatitis CMiddle AgedPrognosisHCV ATHEROSCLEROSI FIBROSISImmunohistochemistryItalyCAROTID ATHEROSCLEROSISFemaleRadiologyAdultmedicine.medical_specialtySettore MED/08 - Anatomia PatologicaCHRONIC HEPATITIS CRisk AssessmentYoung AdultAge DistributionInternal medicineDiabetes mellitusBiopsyHEPATIC FIBROSISConfidence IntervalsmedicineHumansObesitySex DistributionAgedAnalysis of VarianceHepatologybusiness.industryCase-control studyUltrasonography DopplerOdds ratioHepatitis C ChronicHepatologymedicine.diseaseDiabetes Mellitus Type 2Case-Control StudiesMultivariate AnalysisLinear ModelsSteatosisbusinessHepatology
researchProduct

Association of elevated fibrinogen and C-reactive protein levels with carotid lesions in patients with newly diagnosed hypertension or type II diabet…

2006

BACKGROUND: Inflammation may be important for accelerated progression of atherosclerosis in patients with hypertension or diabetes, but few studies included subjects with early stages of atherosclerosis such as those with asymptomatic carotid lesions. METHODS: We studied 100 patients with newly diagnosed hypertension and another 100 patients with newly diagnosed type II diabetes to evaluate in such groups the association of two markers of inflammation, fibrinogen and C-reactive protein (CRP), with carotid atherosclerosis, beyond traditional cardiovascular risk factors (e.g., older age, male gender, obesity, smoking, family history of CAD, dyslipidemia). RESULTS: We found positive correlatio…

Carotid Artery Diseasesmedicine.medical_specialtyInflammationFibrinogenAsymptomaticGastroenterologyInternal medicineDiabetes mellitusmedicineHumansC-reactive protein Hypertension Inflammation Events AtherosclerosisFamily historybiologybusiness.industryC-reactive proteinFibrinogenGeneral Medicinemedicine.diseaseObesityEndocrinologyC-Reactive ProteinCarotid ArteriesDiabetes Mellitus Type 2Hypertensionbiology.proteinmedicine.symptombusinessTunica MediaDyslipidemiamedicine.drugArchives of medical research
researchProduct

Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells.

2007

The cannabinoid system is immunomodulatory and has been targeted as a treatment for the central nervous system (CNS) autoimmune disease multiple sclerosis. Using an animal model of multiple sclerosis, experimental autoimmune encephalomyelitis (EAE), we investigated the role of the CB(1) and CB(2) cannabinoid receptors in regulating CNS autoimmunity. We found that CB(1) receptor expression by neurons, but not T cells, was required for cannabinoid-mediated EAE suppression. In contrast, CB(2) receptor expression by encephalitogenic T cells was critical for controlling inflammation associated with EAE. CB(2)-deficient T cells in the CNS during EAE exhibited reduced levels of apoptosis, a higher…

Central Nervous SystemCannabinoid receptorEncephalomyelitis Autoimmune Experimentalmedicine.medical_treatmentEncephalomyelitisT-LymphocytesInflammationApoptosisMice TransgenicBiologyGeneral Biochemistry Genetics and Molecular BiologyReceptor Cannabinoid CB2MiceReceptor Cannabinoid CB1medicineCannabinoid receptor type 2AnimalsCell ProliferationDNA PrimersAutoimmune diseaseNeuronsExperimental autoimmune encephalomyelitisGeneral Medicinemedicine.diseaseEndocannabinoid systemImmunohistochemistryImmunologyEncephalitislipids (amino acids peptides and proteins)Cannabinoidmedicine.symptomNature medicine
researchProduct

Hypothalamic S-Nitrosylation Contributes to the Counter-Regulatory Response Impairment following Recurrent Hypoglycemia

2013

http://www.ncbi.nlm.nih.gov/pubmed/23894333; International audience; AIMS: Hypoglycemia is a severe side effect of intensive insulin therapy. Recurrent hypoglycemia (RH) impairs the counter-regulatory response (CRR) which restores euglycemia. During hypoglycemia, ventromedial hypothalamus (VMH) production of nitric oxide (NO) and activation of its receptor soluble guanylyl cyclase (sGC) are critical for the CRR. Hypoglycemia also increases brain reactive oxygen species (ROS) production. NO production in the presence of ROS causes protein S-nitrosylation. S-nitrosylation of sGC impairs its function and induces desensitization to NO. We hypothesized that during hypoglycemia, the interaction b…

Central Nervous SystemMaleespèce active de l'oxygènemedicine.medical_treatmentlcsh:Medicinechemistry.chemical_compoundEndocrinology0302 clinical medicineDesensitization (telecommunications)Insulinhypothalamuslcsh:ScienceNeurons0303 health sciencesMultidisciplinaryStatisticsNeurochemistryOrvostudományokAnimal Models[ SDV.MHEP.EM ] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism3. Good healthEpinephrineHomeostatic MechanismsAlimentation et NutritionMedicineNeurochemicalshypoglycémieResearch Articlediabètemedicine.drugmedicine.medical_specialtyRecurrent hypoglycemiamonoxide d'azoteinsulino-thérapie intensiveNeurophysiologyBiostatisticsHypoglycemiaKlinikai orvostudományokNitric OxideGlucagonNitric oxide03 medical and health sciencesModel OrganismsInternal medicinemedicineFood and NutritionAnimalscontre-régulationBiologyNutrition030304 developmental biologyDiabetic EndocrinologyEndocrine Physiologybusiness.industryInsulinlcsh:Rneurone sensible au glucosenutritional and metabolic diseasesmonoxide d'azote;espèce active de l'oxygène;S-nitrosylation;hypoglycémie;neurone sensible au glucose;hypothalamus;contre-régulation;diabète;insulino-thérapie intensiveDiabetes Mellitus Type 1NeuroendocrinologyDiabetes Mellitus Type 2medicine.diseaseHypoglycemiaS-nitrosylationAcetylcysteineRatsGlucoseEndocrinologychemistryMetabolic DisordersRatlcsh:QReactive Oxygen SpeciesbusinessSoluble guanylyl cyclaseMathematics030217 neurology & neurosurgeryNeurosciencePLoS ONE
researchProduct

Metabolic disorders and gastroenteropancreatic-neuroendocrine tumors (GEP-NETs): How do they influence each other? An Italian Association of Medical …

2022

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a heterogeneous group of malignancies derived from neuroendocrine cells that can occur anywhere along the gastrointestinal tract. GEP-NETs incidence has been steadily increasing over the past decades, in parallel with the increasing incidence of the metabolic syndrome (MetS). It is not yet fully known whether the MetS components (such as obesity, dyslipidemia and type 2 diabetes) could be involved in the etiology of GEP-NETs or could influence their outcomes. In this review, a panel of experts of the Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Endocrinology…

ConsensusSettore MED/06 - Oncologia MedicaGEP-NET progressionMetabolic disordersHematologyMedical OncologyMetabolic syndromeNOGEP-NET survivalPancreatic NeoplasmsNeuroendocrine Tumorsgastroenteropancreatic neuroendocrine tumors; gep-net progression; gep-net survival; metabolic disorders; metabolic syndrome; consensus; humans; medical oncology; diabetes mellitus; type 2; intestinal neoplasms; neuroendocrine tumors; pancreatic neoplasms; stomach neoplasmsOncologyGEP-NET progression; GEP-NET survival; Gastroenteropancreatic neuroendocrine tumors; Metabolic disorders; Metabolic syndromeDiabetes Mellitus Type 2Stomach NeoplasmsIntestinal NeoplasmsDiabetes MellitusHumansLS4_3Gastroenteropancreatic neuroendocrine tumorsType 2
researchProduct

Soft drink consumption and unhealthy diet

2013

Consumption (economics)diet soft drinks dietary patternNutrition and Dieteticsbusiness.industryMedicine (miscellaneous)Carbonated BeveragesFeeding BehaviorDietDiabetes Mellitus Type 2Cardiovascular DiseasesSurveys and QuestionnairesEnvironmental healthHumansMedicineObesityFood scienceSettore MED/49 - Scienze Tecniche Dietetiche ApplicatebusinessSoft drinkLife Style
researchProduct

Estimates, trends, and drivers of the global burden of type 2 diabetes attributable to PM2·5 air pollution, 1990–2019: an analysis of data from the G…

2022

Background: Experimental and epidemiological studies indicate an association between exposure to particulate matter (PM) air pollution and increased risk of type 2 diabetes. In view of the high and increasing prevalence of diabetes, we aimed to quantify the burden of type 2 diabetes attributable to PM2·5 originating from ambient and household air pollution.Methods: We systematically compiled all relevant cohort and case-control studies assessing the effect of exposure to household and ambient fine particulate matter (PM2·5) air pollution on type 2 diabetes incidence and mortality. We derived an exposure–response curve from the extracted relative risk estimates using the MR-BRT (meta-regress…

Contaminación del AireHealth (social science)Type II DiabetesType 2 diabetes deathsair pollutionand YLLs attributable to all PM2·5 air pollutionMedicine (miscellaneous)and change from 1990 to 2019DALYsburden of diseaseGlobal Burden of DiseaseCarga Global de EnfermedadesMELLITUSINFLAMMATIONand household PM2·5 pollution from solid fuels in seven GBD super-regions and globally in 2019Diabetes MellitusHumansBiologyASSOCIATIONSRISKINSULIN-RESISTANCEGBD 2019 Diabetes and Air Pollution CollaboratorsHealth PolicyMaterial ParticuladoPublic Health Environmental and Occupational HealthBayes TheoremLONG-TERM EXPOSUREHumanosYLDsChemistryDiabetes Mellitus Type 23121 General medicine internal medicine and other clinical medicineAños de Vida Ajustados por Calidad de Vidaambient PM2·5 pollutionParticulate MatterQuality-Adjusted Life YearsHuman medicineFINE PARTICULATE MATTERRAType II Diabetes; air pollution; burden of disease;The Lancet Planetary Health
researchProduct

The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism

2021

ABSTRACT Introduction A number of anti-diabetic treatments have been favored during the continuing spread of the current SARS-CoV-2 pandemic. Glucagon like peptide-1 receptor agonists (GLP1-RAs) are a group of antidiabetic drugs, the glucose reducing effect of which is founded on augmenting glucose-dependent insulin secretion with concomitant reduction of glucagon secretion and delayed gastric emptying. Apart from their glucose lowering effects, GLP1-RAs also exert a plethora of pleiotropic activities in the form of anti-inflammatory, anti-thrombotic and anti-obesogenic properties, with beneficial cardiovascular and renal impact. All these make this class of drugs a preferred option for man…

Coronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)coronavirusSARS-COV-2PharmacologyIncretinsGlucagonGlucagon-Like Peptide-1 ReceptorAnimalsHumansHypoglycemic AgentsMedicinePharmacology (medical)ReceptorSpecial ReportGlucagon-like peptide 1 receptortherapyPandemicdiabetesSARS-CoV-2business.industrypandemicDiabetesCOVID-19General MedicineGLP-1RAcoronavirus diabetes GLP-1RA pandemic SARS-COV-2 therapy Animals COVID-19Diabetes Mellitus Type 2 Glucagon-Like Peptide-1 Receptor Humans Hypoglycemic Agents Incretins Signal Transduction Treatment OutcomeCOVID-19 Drug TreatmentCoronavirusTreatment OutcomeDiabetes Mellitus Type 2Molecular mechanismbusinessResearch ArticleSignal Transduction
researchProduct